ArticleFrontiers in medicine2025
Constructing the prediction model based on DXA between sarcopenia and BMD in middle-aged and elderly men with T2DM.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of screening tools for diabetic sarcopenia in type 2 diabetes mellitus: evidence from a scoping review.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the relationship between sarcopenia and bone mineral density (BMD) in middle-aged and elderly male patients with type 2 diabetes mellitus (T2DM), construct a prediction model for sarcopenia based on dual-energy X-ray absorptiometry (DXA), and evaluate its clinical value. Methods: A total of 523 middle-aged and elderly male patients with T2DM in the hospital from January 2021 to December 2024 were selected and divided into the training set (366 cases) and the validation set (157 cases) at a ratio of 7:3. The BMD Results: The incidence of sarcopenia was 27.05% (99/366) in the training set and 28.02% (44/157) in the validation set. Multivariate analysis showed that age, HbA1c, and HOMA-IR were independent risk factors for sarcopenia, while the lumbar L1-L4 Conclusion: The prediction model constructed based on DXA can effectively predict the risk of sarcopenia in middle-aged and elderly male patients with T2DM, providing a basis for clinical early screening and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.